TriSalus Life Sciences (TLSI) Gross Profit (2022 - 2026)

TriSalus Life Sciences' Gross Profit history runs 5 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• On a quarterly basis, Gross Profit changed 0.04% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $38.2 million, a 38.78% increase from a year earlier, with the FY2025 full-year figure at $38.2 million, up 50.77% from the prior year.
• Gross Profit eased to $7.7 million in Q1 2026 per TLSI's latest filing, from $11.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $11.4 million in Q4 2025 and bottomed at $2.3 million in Q1 2023.
• The 5-year median for Gross Profit is $6.3 million (2024), against an average of $6.2 million.
• Across the five-year window, Gross Profit surged 136.26% in 2024 and dropped 0.04% in 2026, its largest moves.
• Year by year, Gross Profit stood at $2.4 million in 2022, then surged by 113.24% to $5.1 million in 2023, then surged by 37.09% to $7.0 million in 2024, then jumped by 62.43% to $11.4 million in 2025, then tumbled by 32.98% to $7.7 million in 2026.
• Per Business Quant, the three latest TLSI Gross Profit figures stand at $7.7 million (Q1 2026), $11.4 million (Q4 2025), and $9.7 million (Q3 2025).